New drug cocktail trial aims to tame advanced cancers
NCT ID NCT01187199
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests the safety and best dose of combining two drugs (bevacizumab and temsirolimus) with one of three other cancer drugs for people with advanced cancer that hasn't responded to standard treatments. About 278 participants will receive one of the combinations to find the highest tolerable dose. The goal is to control the disease, not cure it.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A lifeline for cancer caregivers: can simple phone support reduce their stress?
- A digital lifeline: could Real-Time symptom tracking transform care for kids with advanced cancer?
- Can a 30-hour e-learning course equip family doctors to deliver better palliative care?
- Can a new nucleotide analogue boost cancer treatment?
- Can a cancer vaccine train the body to fight advanced tumors?
- Can two targeted drugs boost chemo against a rare Bile-Duct cancer?